MX2024005999A - Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. - Google Patents

Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.

Info

Publication number
MX2024005999A
MX2024005999A MX2024005999A MX2024005999A MX2024005999A MX 2024005999 A MX2024005999 A MX 2024005999A MX 2024005999 A MX2024005999 A MX 2024005999A MX 2024005999 A MX2024005999 A MX 2024005999A MX 2024005999 A MX2024005999 A MX 2024005999A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antigen binding
cancer immunotherapy
antibodies targeting
antibodies
Prior art date
Application number
MX2024005999A
Other languages
English (en)
Spanish (es)
Inventor
Jeng-Horng Her
Po-Lin Huang
Hsin-Ta Hsieh
Ching-Hsuan Hsu
Jhong-Jhe You
Original Assignee
Ap Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ap Biosciences Inc filed Critical Ap Biosciences Inc
Publication of MX2024005999A publication Critical patent/MX2024005999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024005999A 2021-11-19 2022-11-18 Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer. MX2024005999A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163281347P 2021-11-19 2021-11-19
US202263392474P 2022-07-26 2022-07-26
PCT/US2022/050472 WO2023091712A1 (en) 2021-11-19 2022-11-18 Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Publications (1)

Publication Number Publication Date
MX2024005999A true MX2024005999A (es) 2024-05-30

Family

ID=86397821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005999A MX2024005999A (es) 2021-11-19 2022-11-18 Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.

Country Status (9)

Country Link
US (1) US20250026841A1 (enExample)
EP (1) EP4433511A4 (enExample)
JP (1) JP2024540604A (enExample)
KR (1) KR20240101629A9 (enExample)
AU (1) AU2022389917A1 (enExample)
CA (1) CA3237165A1 (enExample)
IL (1) IL312715A (enExample)
MX (1) MX2024005999A (enExample)
WO (1) WO2023091712A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438442B1 (en) * 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
MX2018015022A (es) * 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.
CN109843926B (zh) * 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
BR112021026309A2 (pt) * 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
CN118638240A (zh) * 2019-07-26 2024-09-13 柳韩洋行 抗her2/抗4-1bb双特异性抗体及其用途
KR20220145859A (ko) * 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
JP2023517234A (ja) * 2020-03-09 2023-04-24 アブセレラ バイオロジクス インコーポレイテッド 抗コロナウイルス抗体および使用の方法

Also Published As

Publication number Publication date
US20250026841A1 (en) 2025-01-23
AU2022389917A1 (en) 2024-05-23
JP2024540604A (ja) 2024-10-31
KR20240101629A (ko) 2024-07-02
EP4433511A1 (en) 2024-09-25
IL312715A (en) 2024-07-01
CA3237165A1 (en) 2023-05-25
EP4433511A4 (en) 2026-02-11
KR20240101629A9 (ko) 2025-12-10
WO2023091712A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
PH12021552831A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
TN2014000148A1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
MY182444A (en) Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.
MX2024014288A (es) Agentes de union a nectina-4
BR112018008983A2 (pt) moléculas de ligação específicas para asct2 e seus usos
WO2019241893A3 (en) Anti-her3 antibody and uses thereof
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
BR112021026309A2 (pt) Anticorpos para ativação de células t
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
MX2024004048A (es) Conjugado anticuerpo-farmaco anti-cd37.
MX2025006057A (es) Conjugados anticuerpo-farmaco anti-cea y metodos de uso
MX2025002569A (es) Anticuerpos anti-trop2/egfr y usos de estos
MX2024009292A (es) Anticuerpos anti-her2/trop2 y usos de los mismos.
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
MX2025014033A (es) Anticuerpos y sus conjugados de anticuerpo y farmaco
MX2025003153A (es) Anticuerpos anti-ccr8
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
WO2022112942A3 (en) Anti-cd48 antibodies, antibody drug conjugates, and uses thereof